Key Highlights

● COYA shares rose 4.62% to $4.76 on Friday.

● Coya Therapeutics is a micro-cap, clinical-stage biotechnology company developing regulatory-T-cell, or Treg, based immunotherapies, with lead candidate COYA 302 in development for ALS.

● The company reported second-quarter 2026 cash of about $43.2 million, with a runway guided to fund operations past its key ALS trial readout into the second half of 2027.

● Coya holds a fast-track designation for COYA 302 and has a global-license Partnership with a large pharmaceutical company, with enrollment on track to complete in 2026 and topline data expected in early 2027.

Coya Therapeutics, Inc. (NASDAQ:COYA) shares rose 4.62% to $4.76 on Friday. Coya is a micro-cap, clinical-stage biotechnology company developing regulatory-T-cell, or Treg, based immunotherapies for neurodegenerative and other conditions, with its lead candidate, COYA 302, in development for amyotrophic lateral sclerosis, or ALS.

The company is pre-revenue apart from small collaboration income, and its value is tied almost entirely to the outcome of its key ALS trial, with topline data expected in early 2027.

Latest Developments

In its second-quarter 2026 results, Coya reported a net loss of about $6.6 million and cash of about $43.2 million, with a runway guided to fund operations past the topline data readout of its lead ALS trial and into the second half of 2027. The company said enrollment was proceeding as planned, on track to complete in 2026 with topline data expected in early 2027, and it holds a fast-track designation along with a global-license partnership with a large pharmaceutical company on COYA 302.

Financial and Business Position

As a pre-revenue clinical-stage micro-cap, Coya's financial position is defined by its cash, which is guided to fund it past its key ALS data readout, its ongoing losses and cash burn, and its partnership, so its future depends almost entirely on that readout and on advancing COYA 302.

Stock-Market Context

COYA is a speculative, single-asset clinical-stage biotech whose shares are highly volatile and sensitive to trial progress, cash position, and the partnership. Friday's sharp gain reflects renewed investor interest, supported by the funded runway, fast-track designation, on-schedule enrollment, and the big-pharma partnership, even though the stock's value will effectively live or die on its early-2027 ALS data readout.

What Investors Should Watch

Watch the trial's enrollment progress, the timing and outcome of the early-2027 topline data readout, cash position and burn, and developments in the partnership. On-schedule enrollment and a positive data readout would be the clearest fundamental catalysts, while a disappointing readout or unexpected cash burn would be the principal risks.

The binary nature of Coya's business, tied to a single pivotal trial, means the stock can be highly volatile in either direction as investors reassess the probability of trial success based on incremental updates.

The 2027 Readout Is the Defining Catalyst

Coya's funded runway through its key ALS trial readout, fast-track designation, and big-pharma partnership provide meaningful support, but the stock's ultimate value depends almost entirely on the early-2027 topline data. Watching enrollment updates and any interim disclosures over the coming months is the clearest way to track the fundamental picture ahead of that readout.